Scarica l'app Stockscreener
66.25
0.68%
0.45
Dopo l'orario di chiusura:
66.70
0.45
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$65.80
Aprire:
$66.43
Volume 24 ore:
1.18M
Relative Volume:
0.65
Capitalizzazione di mercato:
$8.23B
Reddito:
$88.04M
Utile/perdita netta:
$-784.96M
Rapporto P/E:
-10.14
EPS:
-6.5335
Flusso di cassa netto:
$-534.82M
1 W Prestazione:
+1.35%
1M Prestazione:
+7.37%
6M Prestazione:
+20.98%
1 anno Prestazione:
+75.22%
Intervallo 1D:
$64.99
$66.51
Intervallo di 1 settimana:
$63.97
$67.04
Portata 52W:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.25 | 8.17B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Wells Fargo | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $229,915 of company stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $229,915 of company stock - Investing.com
Cytokinetics (CYTK) EVP sells 3,500 shares after option exercise - Stock Titan
Cytokinetics to Announce First Quarter Results on May 5, 2026 - Yahoo Finance
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics Inc stock (US2328281044): Does its cardiac muscle inhibitor pipeline now become the tur - AD HOC NEWS
Cytokinetics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Cytokinetics awards equity grants to 33 new hires under Nasdaq rule - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: A 39% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up - TipRanks
Cytokinetics Incorporated : 2025 Annual Report of 2025 - marketscreener.com
[DEF 14A] CYTOKINETICS INC Definitive Proxy Statement - Stock Titan
Can Myqorzo Drive Growth for Cytokinetics Amid Competition? - Yahoo Finance
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cytokinetics Insider Sold Shares Worth $491,783, According to a Recent SEC Filing - Moomoo
Massachusetts Financial Services Co. MA Cuts Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Insider Sell: Andrew Callos Sells 7,449 Shares of Cytokinetics I - GuruFocus
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares, retains large stake - Stock Titan
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock - Investing.com
Director at CYTOKINETICS (CYTK) receives 95-share equity grant in lieu of cash - Stock Titan
Cytokinetics EVP Callos sells $491k in stock By Investing.com - Investing.com India
Blum Robert I, president & CEO of Cytokinetics, sells $490k in stock By Investing.com - Investing.com South Africa
Cytokinetics (NASDAQ: CYTK) director receives 95-share equity grant - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) director receives 191-share equity grant as retainer - Stock Titan
Cytokinetics EVP Callos sells $491k in stock - Investing.com
Andrew Callos Sells 7,449 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
CYTOKINETICS (CYTK) EVP Andrew Callos sells 7,449 shares in open market - Stock Titan
Andrew Callos sells via 10b5-1; CYTK (NASDAQ: CYTK) insider filings - Stock Titan
Cytokinetics Incorporated : Read Our 2025 Report - marketscreener.com
Cytokinetics Highlights MYQORZO Launch Progress, Teases 2026 Phase 3 Readout at Needham Conference - MarketBeat
Cytokinetics Inc stock (US2328281044): Does cardiac muscle therapy execution now define its biotech - AD HOC NEWS
Fed Watch: Is Cytokinetics Incorporated undervalued by DCF analysisSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
CYTK Analyst Rating: Wells Fargo Initiates Overweight April 2026 - Meyka
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Q1 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc at JMP Securities Life Sciences Conference Transcript - GuruFocus
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Earnings Transcripts - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock News, Headlines & Updates - GuruFocus
Market Review: What are the future prospects of Cytokinetics IncorporatedAnalyst Downgrade & Real-Time Price Movement Reports - baoquankhu1.vn
Wells Fargo initiates coverage of Cytokinetics (CYTK) with overweight recommendation - MSN
CYTK Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Momentum Shift: Is Cytokinetics Incorporated stock heavily shortedWeekly Profit Analysis & Scalable Portfolio Growth Methods - baoquankhu1.vn
Risk Recap: Will Cytokinetics Incorporated stock go up in YEAR2026 Pullback Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Cytokinetics Inc (HAM:KK3A) Valuation: Possible Value Trap, Think Twice - GuruFocus
Cytokinetics Inc (HAM:KK3A) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Cytokinetics Inc (HAM:KK3A) Stock Today? - GuruFocus
Cytokinetics Inc Stock Operating Data - GuruFocus
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Apr 21 '26 |
Sale |
65.69 |
3,500 |
229,915 |
153,902 |
| Callos Andrew | EVP, Chief Commercial Officer |
Apr 15 '26 |
Sale |
66.02 |
7,449 |
491,783 |
58,555 |
| Blum Robert I | President & CEO |
Apr 15 '26 |
Sale |
65.38 |
7,500 |
490,350 |
415,330 |
2.53%
2.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):